Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study

Crohn's Disease Clinical Trial

Official title:

Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00596700
• Other study ID #: CECDAI-2006
• Status: Completed
• Phase: Phase 3
• First received: January 8, 2008
• Last updated: April 28, 2014
• Start date: January 2007
• Est. completion date: January 2012

Study information

• Verified date: April 2014
• Source: Rabin Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The Study

1. Prospective trial of the Niv score validating score against known activity indices - see addendum A for Niv score

2. Known Crohn's disease patients undergoing capsule endoscopy are identified - see addendum B for inclusion/exclusion criteria

3. Prior to capsule exam, temperature is taken, height and weight measured, bloods are drawn for albumin, ESR, HCT, CRP

4. Prior to capsule exam, symptom/exam questionnaire is completed - see addendum C for questionnaire

5. Capsule exam is performed

6. CD of de-identified is made at the study site.

7. Landmarks are confirmed and the small bowel transit time is divided into 2 and labeled on thumbnails

8. CDs are copied

9. CDs of study patients are provided to blinded readers

Description:

The Niv score was devised to measure mucosal disease activity in Crohn's disease using capsule endoscopy. This scoring index is based on inflammatory score parameters: Erythema, hyperemia, edema, denudation, nodularity, apthae, erosion, ulcer, bleeding), extent score: Focal, patchy, diffuse, and stricture score: single-passed, multiple-passed, obstruction. The higher the score, the more involvement is observed. The advantage of this index is that it actually measures disease activity and not symptoms in an easy non-invasive manner. For assessing Crohn's disease, mucosal healing can be directly seen and if there is no mucosal disease there can be no symptoms secondary to inflammatory bowel disease. The subjective nature of disease activity indices is avoided, as is the problem of disease without symptoms. It is envisioned that the Niv score could diagnose Crohn's disease (excluding normally occurring mucosal breaks), identify NSAID damage, measure disease activity / severity, measure drug response for clinical trials and in practice, and guide medical management for the patient's with small bowel Crohn's disease.

This study will measure the Niv score against CDAI. Since capsule endoscopy assesses mucosal disease and not symptoms it is not envisioned that the Niv score will perfectly correlate with the Harvey-Bradshaw score. It is envisioned that the Niv score will have the same direction. Both of these indices will be determined as part of a multicenter trial. The trial design is outlined below.

The Study

1. Prospective trial of the Niv score validating score against known activity indices - see addendum A for Niv score

2. Known Crohn's disease patients undergoing capsule endoscopy are identified - see addendum B for inclusion/exclusion criteria

3. Prior to capsule exam, temperature is taken, height and weight measured, bloods are drawn for albumin, ESR, HCT, CRP

4. Prior to capsule exam, symptom/exam questionnaire is completed - see addendum C for questionnaire

5. Capsule exam is performed

6. CD of de-identified is made at the study site.

7. Landmarks are confirmed and the small bowel transit time is divided into 2 and labeled on thumbnails

8. CDs are copied

9. CDs of study patients are provided to blinded readers

Scoring sheets will be provided to readers - see addendum A

10. Readers will score the CDs and return the scoring sheets to the principal investigator

11. Data is collated and analyzed

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients 18 years or older and not greater than 80 years suffer from Crohn's Disease of the small bowel, documented by clinical, endoscopical, histopathological and radiological parameters, in any activity stage iof the disease and any treatment

• Documented written Informed Consent

Exclusion Criteria:

• Subject suffers from swallowing difficulties

• Female subject is pregnant or nursing (in case of necessary small bowel series a pregnancy test has to be performed prior to the test)

• Subject is known to suffer from intestinal obstruction

• Subject has a cardiac pacemakers or other implanted electro medical devices

• Patients with more than 40% small bowel resect

• Subject has any condition, which precludes compliance with study and/or device instructions

• Subject suffers from life threatening conditions

• Subject is currently participating in another clinical study

• Subject with colonic involvement of Crohn's disease

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Device:
• Given® Diagnostic System including PillCamTM SB Capsules
Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders. An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa

Locations

Country	Name	City	State
Ireland	Triniti College	Dublin
Israel	Hillel Jafa Medical Center	Hadera
Israel	Rabin Medical Center, Beilinson Hospital, Tel Aviv University	Petach Tikva
Israel	Asaf Harofe Medical Center	Zrifin

Sponsors (7)

Lead Sponsor	Collaborator
Rabin Medical Center	Assaf-Harofeh Medical Center, Hillel Yaffe Medical Center, Rambam Health Care Campus, University of Athens, University of Magdeburg, VA Office of Research and Development

Countries where clinical trial is conducted

Ireland,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	This prospective study is aimed to evaluate the correlation of capsule endoscopy CECDAI with the CDAI (accepted clinical index) and IBDQ (quality of life questionnaire) in patients suffering from small-bowel Crohn's disease		Two years	Yes
Secondary	Capsule endoscopy investigation and crohn's disease outcome		Two years	Yes